82 Results for "

Chk2

" in MedChemExpress (MCE) Product Catalog:
Products (82)

82 Results for "Chk2" in MCE Product Catalog:

Cat. No.: HY-153857
CAS No.: 2127107-15-5
Purity:  98.97%
Synonyms: PHI-101
Research Areas:  

Cancer

Lasmotinib (PHI-101) is a FLT3 and CHK2 inhibitor. Lasmotinib potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. Lasmotinib synergizes with Venetoclax (HY-15531) or Azacytidine to inhibit leukemia. Lasmotinib exhibits anticancer activity against ovarian and breast cancer [2] .
loading...
    loading...
Cat. No.: HY-160096
CAS No.: 1360628-91-6
Research Areas:  

Cancer

M3541 is an orally effective DNA-dependent protein kinase (DNA-PK) inhibitor . M3541 inhibits ionizing radiation-induced ATM autophosphorylation and phosphorylation of downstream substrates (KAP1, CHK2, p53), blocks DSB end resection and homologous recombination repair, and simultaneously induces non-homologous end joining, G2-M phase arrest, polyploidization, and cell death. M3541 can be used for research on solid tumors, acute myeloid leukemia, non-small cell lung cancer, triple-negative breast cancer, etc. [2] .
loading...
    loading...
Cat. No.: HY-15883
CAS No.: 1200126-26-6
Purity:  99.21%
Research Areas:  

Cancer

GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC50s of 0.0011, 1.5 μM for ChKl, ChK2, respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis. Gemcitabine (HY-17026) and GNE-900 administration shows anti-tumor activity .
loading...
    loading...
Cat. No.: HY-16129
CAS No.: 565434-85-7
CBP-501, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser 216-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC50 values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 is used for various types of cancer [2].
loading...
    loading...
Cat. No.: HY-117102
CAS No.: 931417-26-4
Purity:  98.13%
Research Areas:  

Cancer

ANI-7 is an activator of aryl hydrocarbon receptor (AhR) pathway. ANI-7 inhibits the growth of multiple cancer cells, and potently and selectively inhibits the growth of MCF-7 breast cancer cells with a GI50 of 0.56 μM. ANI-7 induces CYP1-metabolizing mono-oxygenases by activating AhR pathway, and also induces DNA damage, checkpoint Kinase 2 (Chk2) activation, S-phase cell cycle arrest, and cell death in sensitive breast cancer cell lines [2] .
loading...
    loading...
Cat. No.: HY-14715
CAS No.: 1262849-73-9
Research Areas:  

Cancer

CCT241533 is a potent and selective ATP competitive inhibitor of CHK2 with an IC50 of 3 nM and Ki of 1.16 nM .
loading...
    loading...
Cat. No.: HY-164496
CAS No.: 1161826-19-2
Target:  

DNA/RNA Synthesis

Research Areas:  

Neurological Disease Cancer

KL-50 is an orally active N3-(2-fluoroethyl) imidazotetrazine DNA alkylating agent with selectivity for MGMT-deficient cells. KL-50 introduces a 2-fluoroethyl group at the O6 position of guanine, forming O6-(2-fluoroethyl) guanine (O6FEtG) lesions and further generating DNA interstrand crosslinks (ICLs). KL-50 induces DNA double-strand breaks, activates ATR-CHK1 and ATM-CHK2 DNA damage responses, and causes cell cycle arrest and micronucleus formation. KL-50 can be used for glioblastoma and DNA damage response research [2] .
loading...
    loading...
Cat. No.: HY-112477
CAS No.: 724708-21-8
Synonyms: Hymenialdisine analogue-1
Research Areas:  

Cancer

Chk2-IN-1 (compound 1) is a potent and selective inhibitor of checkpoint kinase 2 (Chk2), with IC50s of 13.5 nM and 220.4 nM for Chk2 and Chk1, respectively. Chk2-IN-1 can elicit a strong ataxia telangiectasia mutated (ATM)-dependent Chk2-mediated radioprotection effect .
loading...
    loading...
Cat. No.: HY-18174H
CAS No.: 2781996-46-9
Synonyms: LY2606368 lactate
Research Areas:  

Cancer

Prexasertib lactate (LY2606368 lactate) is the lactate form of Prexasertib (HY-18174). Prexasertib lactate is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib lactate inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib lactate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib lactate shows potent anti-tumor activity [2].
loading...
    loading...
Cat. No.: HY-106009
CAS No.: 926906-64-1
Purity:  99.91%
Research Areas:  

Cancer

VRX0466617 is a selective and ATP-competitive Chk2 inhibitor with an IC50 of 120 nM and a Ki of 11 nM. VRX0466617 does not inhibit the related Chk1 activity. VRX0466617 can be used in the study of cancer.
loading...
    loading...
Cat. No.: HY-B1165R
CAS No.: 41354-29-4
Cyproheptadine hydrochloride sesquihydrate (Standard) is the analytical standard of Cyproheptadine hydrochloride sesquihydrate (HY-B1165). This product is intended for research and analytical applications. Cyproheptadine hydrochloride sesquihydrate acts as a p38 MAP kinase activator, CHK2 activator, histamine H1 receptor inhibitor and serotonin receptor inhibitor. Cyproheptadine hydrochloride sesquihydrate mediates cell cycle arrest via G1 phase arrest, G1/S transition arrest, G0/G1 phase arrest, reduced expression of cyclins D1/D2/D3, upregulated expression of HBP1, p16, p21, p27, and decreased phosphorylation of retinoblastoma protein. Cyproheptadine hydrochloride sesquihydrate induces Apoptosis by increasing PARP and cleaved PARP, as well as activating the mitochondrial caspase pathway. Cyproheptadine hydrochloride sesquihydrate inhibits tumor growth with extremely low toxicity to normal cells. Cyproheptadine hydrochloride sesquihydrate can be used in research related to hepatocellular carcinoma, multiple myeloma and acute myeloid leukemia [2].
loading...
    loading...
Cat. No.: HY-164523
CAS No.: 1093793-11-3
Research Areas:  

Cancer

PV1162 is a selective Chk2 inhibitor with an IC50 of 0.29 nM. PV1162 inhibits ATP binding to Chk2 by targeting the gatekeeper-dependent hydrophobic pocket, which is specific to Chk2 and located behind the ATP-binding site (adenine-binding region), thereby inhibiting the phosphorylation activity of Chk2. PV1162 holds potential application value in the field of cancer therapy .
loading...
    loading...
Cat. No.: HY-110331
CAS No.: 1962925-28-5
Research Areas:  

Cancer

CCT241533 dihydrochloride is a potent and selective ATP competitive inhibitor of CHK2 with an IC50 of 3 nM and Ki of 1.16 nM .
loading...
    loading...
Cat. No.: HY-158303
CAS No.: 2984543-29-3
Research Areas:  

Cancer

Chk2-IN-2 (compound 2) is a selective inhibitor of CHK2 with potential anticancer activity .
loading...
    loading...
Cat. No.: HY-18942
CAS No.: 1174664-88-0
Research Areas:  

Cancer

VER-00158411 is a checkpoint kinase 1 (CHK1) and CHK2 inhibitor with IC50 values of 4.4 nM and 4.5 nM, respectively .
loading...
    loading...
Cat. No.: HY-124122
CAS No.: 1802665-43-5
BPTQ is a potent inhibitor against VEGFR1 and CHK2 with IC50 values of 0.54 and 1.70 µmol/L, respectively. BPTQ is also an intercalator of DNA with anticancer activities. BPTQ inhibits the proliferation of HL-60 cells by arresting cells at S and G2/M phase with an IC50 value of 12 µmol/L. BPTQ also activates the mitochondria-mediated Apoptosis pathway by a decrease in mitochondrial membrane potential, increase in the Bax:Bcl-2 ratio and activation of caspases [2].
loading...
    loading...
Cat. No.: HY-156916
CAS No.: 93326-70-6
WAY-230563 (ST045945) is a serine/threonine kinase inhibitor that can block CHK1/CHK2-mediated cell cycle checkpoints. WAY-230563 can induce G2/M phase arrest and DNA damage in tumor cells .
loading...
    loading...
Cat. No.: HY-119699
CAS No.: 1093793-10-2
Research Areas:  

Cancer

PV1115 is a potent and highly selective Chk2 inhibitor with an IC50 of 0.14 nM, 66000 nM, >100000 nM for Chk2, Chk1 and RSK2, respectively. PV1115 is situated within the ATP-binding pocket of Chk2 .
loading...
    loading...
Cat. No.: HY-124774
CAS No.: 631864-00-1
Synonyms: EXEL-9844
Research Areas:  

Cancer

XL-844 (EXEL-9844) is an inhibitor of Chk1 and Chk2. XL-844 exhibits antineoplastic activity. XL-844 can result in tumor cell apoptosis through inhibition of cell cycle arrest. XL-844 inhibits VEGFR1 and VEGFR3. XL-844 can be studied in anti-cancer research .
loading...
    loading...
Cat. No.: HY-18174B
CAS No.: 1234015-57-6
Synonyms: LY2606368 Mesylate Hydrate; LY2940930
Research Areas:  

Cancer

Prexasertib Mesylate Hydrate (LY2606368 Mesylate Hydrate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib Mesylate Hydrate inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib Mesylate Hydrate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib Mesylate Hydrate shows potent anti-tumor activity [2].
loading...
    loading...